EDAP Opens Its First HIFU Prostate Cancer Treatment Center in Australia

Share Name	Share Symbol	Market	Type
EDAP TMS SA	NASDAQ:EDAP	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.21	4.21%	5.195	5.16	5.25	5.2585	5.00	5.108	29,240	20:50:13

EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart

From Jul 2019 to Jul 2024

Ablatherm(R)-HIFU Treatments Begin in Sydney LYON, France, Oct. 12 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ: EDAP), the world leader in High Intensity Focused Ultrasound treatment of localized prostate cancer, is pleased to announce the launch of the first Ablatherm(R)-HIFU treatment center for localized prostate cancer in Australia. An Ablatherm-HIFU device is now available at the highly regarded St Vincent's Clinic, Sydney, Australia, one of 34 facilities in the Sisters of Charity Health Service System. The clinic is the largest center in Australia for Prostate cancer and a multi-disciplinary Clinic of Excellence, including the St Vincent's Prostate Cancer Centre, providing a comprehensive range of investigative, diagnostic and therapeutic services for patients. Pr. Phillip Stricker, Head of Urology, and Dr. David Golovsky, Urologist, will be using the Ablatherm. Pr. Phillip Stricker, who has one of the largest experiences in treating men with prostate cancer using surgery or brachytherapy, commented: "I am very pleased to begin offering this highly regarded treatment in Australia. Ablatherm-HIFU has now been used for more than 10 years in many countries. Fifteen clinical articles have been published and over 7,000 patients treated. This makes it the most developed HIFU solution in the world. Ablatherm-HIFU has excellent safety features all of which have been proven in clinical trials. EDAP continues to advance the technology with ever more refined imaging solutions. In addition, it supports an expanding body of treatment data compiled over now more than ten years worldwide. Ablatherm-HIFU is an important addition to the portfolio of therapies offered to patients at the St Vincent's Clinic." More than 11,200 men are diagnosed with prostate cancer every year in Australia. St Vincent's Clinic, with its Ablatherm-HIFU, will be able to offer a proven, minimally invasive solution for patients with localized prostate cancer who cannot undergo surgery, fail radiotherapy or prefer the low side effects of Ablatherm-HIFU therapy in order to preserve their quality of life. More than 90 percent of patients can be treated by a single procedure usually lasting two to three hours. Due to its uniquely noninvasive nature and low side effects, patients may be discharged as early as a few hours after the procedure. Ablatherm-HIFU is a precise, targeted procedure that delivers a beam of high-intensity focused ultrasound to the prostate. A probe is placed into the rectum through which the focused ultrasound waves are directed into the cancerous prostate tissue without damage to other tissue. A rapid rise in temperature inside the prostate to 85 degrees Celsius destroys the cancerous cells. The procedure is completed without blood loss or exposure to potential harmful radiation. Ablatherm-HIFU is an effective treatment for patients with localized prostate cancer whose disease is confined to the prostate gland itself, referred to as clinical stage T1 or T2. It also can be performed on patients who have undergone radiation treatment in the past and experienced recurrent cancer. The HIFU procedure provides these patients with a unique alternative treatment option preserving their quality of life, when few other choices remain. EDAP's Ablatherm-HIFU was approved in April 2005 by the Australian Therapeutic Goods Administration (TGA). EDAP subsequently began work to secure a clinical site and dedicated practitioner team. St Vincent's Clinic has been offering the Ablatherm-HIFU solution to Australian men since October 7, 2005. The treatment will be provided through the company's unique cost-per-procedure model, allowing urologists to offer the procedure on a cost effective basis. Pr. Phillip Stricker commented: "In reviewing the clinical data, a clear pattern of success is evident. Ablatherm-HIFU studies done in Europe showed that 93 percent of patients had negative biopsies and 87 percent had Prostatic Specific Antigen (PSA) levels of less than 1.0, five years after having the Ablatherm-HIFU treatment. These studies, along with many others, conclude that Ablatherm-HIFU is an effective prostate cancer treatment that offers patients a logical alternative to the other more invasive treatments commonly used." Hugues de Bantel, CEO of EDAP commented: "We are very pleased to begin providing Ablatherm-HIFU treatments in Australia. As is our model, we successfully secured approval to offer the treatment in Australia, then began developing relationships with well respected practitioners in the area. We expect more urologists will wish to offer Ablatherm-HIFU as a part of their treatment portfolio once they have been able to observe the unique and compelling benefits of this treatment. Pr. Stricker and Dr. Golovsky have a large body of clinical experience in treating prostate cancer, and we are pleased to have them join leading urologists worldwide in offering this beneficial therapy to patients." Hugues de Bantel continued: "EDAP continues to execute on its operating plans to open new markets for Ablatherm- HIFU, continue growth in existing markets through increased use on unit sold as well as our unique cost per procedure model, and expand on its Ablatherm's base of highly regarded and respected practitioners who serve an important role in educating both physicians and patients about the choices available to them in treating localized prostate cancer. We continue to focus on building our position as the provider with the most advanced technology, the largest and longest clinical data and the most supportive services assisting practitioners in bringing this important treatment option to patients. As a result, we are now treating patients at more than 76 sites in 15 countries around the world and continue to increase the number of patients treated each year, the number of sites we serve and the worldwide reach of our unique and beneficial treatment. We look forward to continuing to report our progress in these initiatives." Additional information about Ablatherm-HIFU treatment in Australia can be found at http://www.prostate.com.au/ or call the St Vincent's Prostate Cancer Centre on +61 2 8382 6530. About EDAP TMS S.A. EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. The company is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL). For more information on the Company, contact the Investor Relations Dept by phone at +33 (0)4 78 26 40 46 or see the Company's Web site at: http://www.edap-tms.com/. About St Vincent's Clinic: In 1990, St Vincent's Clinic opened its doors to offer a service unparalleled in Australia. A joint effort between the Sisters of Charity and a number of specialists, the Clinic has grown into a Centre of Excellence, providing a comprehensive range of patient services. There are over 200 doctors and a range of allied health services located at the Clinic. The Clinic is one of the thirty-four facilities (including public and private hospitals, sub-acute facilities, residential aged care facilities, research centres and Outreach services) of the Sisters of Charity Health Service. The emphasis on excellence in medical care is strengthened by the Clinic's commitment to research and education. This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. CONTACT: EDAP TMS S.A. Hugues de Bantel - Philippe Chauveau Blandine Confort +33 4 78 26 40 46 Halliburton Investor Relations Matt Kreps - Geralyn DeBusk +1 972 458 8000 DATASOURCE: EDAP TMS S.A. CONTACT: Hugues de Bantel, or Philippe Chauveau, or Blandine Confort, +33-4-78-26-40-46, all of EDAP TMS S.A., or Matt Kreps, or Geralyn DeBusk of Halliburton Investor Relations, +1-972-458-8000 Web site: http://www.edap-tms.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

EDAP EDAP TMS SA